Detalles de la búsqueda
1.
Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet
; 393(10173): 778-790, 2019 02 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-30792007
2.
Treating Opioid Use Disorder With a Monthly Subcutaneous Buprenorphine Depot Injection: 12-Month Safety, Tolerability, and Efficacy Analysis.
J Clin Psychopharmacol
; 40(3): 231-239, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32282418
3.
18-Month efficacy and safety analysis of monthly subcutaneous buprenorphine injection for opioid use disorder: Integrated analysis of phase 3 studies.
J Subst Use Addict Treat
; 154: 209155, 2023 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37657559
4.
Folate metabolism biomarkers from two randomised placebo-controlled clinical studies with paroxetine and venlafaxine.
World J Biol Psychiatry
; 22(4): 315-321, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32787676
5.
Assessment of craving in opioid use disorder: Psychometric evaluation and predictive validity of the opioid craving VAS.
Drug Alcohol Depend
; 229(Pt B): 109057, 2021 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34794061
6.
Effects of monthly buprenorphine extended-release injections on patient-centered outcomes: A long-term study.
J Subst Abuse Treat
; 110: 1-8, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-31952623
7.
Recovery From Opioid Use Disorder (OUD) After Monthly Long-acting Buprenorphine Treatment: 12-Month Longitudinal Outcomes From RECOVER, an Observational Study.
J Addict Med
; 14(5): e233-e240, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32187112
8.
Biomarkers for response in major depression: comparing paroxetine and venlafaxine from two randomised placebo-controlled clinical studies.
Transl Psychiatry
; 9(1): 182, 2019 08 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31375659
9.
Patient-centered Outcomes in Participants of a Buprenorphine Monthly Depot (BUP-XR) Double-blind, Placebo-controlled, Multicenter, Phase 3 Study.
J Addict Med
; 13(6): 442-449, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-30844878
10.
Remission from chronic opioid use-Studying environmental and socio-economic factors on recovery (RECOVER): Study design and participant characteristics.
Contemp Clin Trials
; 76: 93-103, 2019 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30508592
11.
Measuring recovery in opioid use disorder: clinical utility and psychometric properties of the Treatment Effectiveness Assessment.
Subst Abuse Rehabil
; 10: 13-21, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31239805
12.
Patient-reported outcomes in schizophrenia patients treated with once-monthly extended-release risperidone in a long-term clinical study.
Patient Prefer Adherence
; 13: 1037-1050, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31308636
13.
Pharmacokinetics of Sublingual Buprenorphine Tablets Following Single and Multiple Doses in Chinese Participants With and Without Opioid Use Disorder.
Drugs R D
; 19(3): 255-265, 2019 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-31197606
14.
Evaluation of antidepressant properties of the p38 MAP kinase inhibitor losmapimod (GW856553) in Major Depressive Disorder: Results from two randomised, placebo-controlled, double-blind, multicentre studies using a Bayesian approach.
J Psychopharmacol
; 28(6): 570-81, 2014 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-24699061
15.
Efficacy, safety, and tolerability of a triple reuptake inhibitor GSK372475 in the treatment of patients with major depressive disorder: two randomized, placebo- and active-controlled clinical trials.
J Psychopharmacol
; 26(5): 653-62, 2012 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-22048884
Resultados
1 -
15
de 15
1
Próxima >
>>